MSC-Derived Exosomes

Overview

Parent Cell: UCT-WJ-Mesenchymal Stem Cells (undifferentiated) | Broad-spectrum regenerative and immunomodulatory exosome matrix; the foundational exosome product providing anti-inflammatory, anti-fibrotic, and pro-angiogenic bioactive molecules

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Trend analyses of MSC-EV clinical trials find that efficacy does not scale indefinitely with dose and instead concentrates within a narrower optimal range.^[1]

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

Mechanism of Action & Molecular Cargo

Immunomodulation: miR-146a, miR-21, and PGE2 suppress NF-κB signaling, reduce TNF-α/IL-1β/IL-6 production, and shift macrophage polarization from M1 to M2 — providing systemic anti-inflammatory effects relevant across autoimmune, inflammatory, and degenerative conditions.

Anti-Fibrosis: miR-let7, miR-29, and TGF-β modulators suppress fibroblast-to-myofibroblast transition and reduce collagen deposition — slowing fibrotic progression in liver, kidney, lung, and skin.

Angiogenesis: VEGF mRNA, miR-132, and PDGF in exosomal cargo activate endothelial proliferation and tube formation — supporting wound healing, ischemic tissue repair, and organ regeneration.

Cell Survival & Anti-Apoptosis: Bcl-2 upregulation via miR-21 (PTEN suppression → PI3K/Akt activation) protects stressed cells from apoptosis in ischemic, toxic, and inflammatory injury contexts.

Cross the Blood-Brain Barrier: Exosomes' lipid bilayer membrane enables CNS penetration following IV delivery — providing neurological therapeutic effects without direct CNS injection.

Key Molecular Cargo

Potential Applications

• Rheumatoid Arthritis, Psoriasis, Multiple Sclerosis, Lupus (SLE)
• Crohn's Disease, Ulcerative Colitis, IBD
• Type 1 & Type 2 Diabetes — systemic immunomodulation beta cell support
• Osteoarthritis — intra-articular delivery
• COPD / Pulmonary Fibrosis — anti-fibrotic, alveolar repair
• Liver Failure / Cirrhosis — hepatoprotective paracrine effects
• Chronic Kidney Disease — anti-fibrotic, renoprotective
• Post-COVID Systemic Inflammation
• Graft-versus-Host Disease (GvHD)
• Erectile Dysfunction — endothelial support
• Intervertebral Disc Degeneration
• General Anti-Aging / Wellness — systemic inflammation reduction

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

A 2023 comprehensive review (Stem Cell Res Ther, PMC10079493) catalogued 46+ clinical trials globally using MSC-derived exosomes across immunological, regenerative, and neurological indications — confirming the safety and emerging efficacy of UCT-MSC exosomes across multiple organ systems.^[2]

A 2024 clinical case series found that combining MSC exosomes with RF microneedling significantly enhanced collagen production vs either treatment alone — confirming exosome delivery compatibility with standard clinical dermatological protocols.^[3]

Published data from 2023 reviews confirm MSC exosome preparations consistently reduce systemic inflammatory markers (CRP, IL-6, TNF-α) by 40–65% in preclinical inflammation models, with 4–8 week duration of effect per IV infusion.

In GvHD models, MSC exosomes suppress allo-reactive T-cell proliferation by 55–70% in mixed lymphocyte reactions — with direct clinical relevance confirmed in Phase I GvHD trials using parent WJ-MSC cells.^[4]

A 2025 preclinical-to-clinical review of intra-articular hucMSC exosomes for knee osteoarthritis found consistent pain and function improvement with a favorable safety profile across the studies reviewed.^[5]

hucMSC exosomes targeting macrophage polarization (via INS/SOD1 delivery) attenuated systemic inflammation in a 2025 T1DM study, supporting the same macrophage-repolarization mechanism underlying this product's broader immunomodulatory profile.^[6]